Monash IVF Embryo Bungles: Independent Review Remains Secret to Protect Patient Privacy.

An independent review into Monash IVF embryo bungles in Melbourne and Brisbane has found that the Brisbane incident was caused by human error, while the Melbourne incident resulted from a combination of human error and IT system limitations. The review, conducted by barrister Fiona McLeod, will remain secret to protect patient privacy. Monash IVF has implemented many of the review's recommendations and is committed to implementing the remainder.

INVO Fertility (IVF) reported its fiscal 2025 Q2 earnings on August 14, 2025, with a mixed bag of results that highlight the company's ongoing financial struggles. The company narrowed its per-share loss to $13.30, a 40.6% improvement from the prior year's $22.39, but saw a 135.4% wider net loss, expanding to $5.28 million [1].

Total revenue grew marginally by 1.5% to $1.86 million, driven primarily by clinic services, which generated $1.83 million, with product sales contributing $31,560. This reflects INVO Fertility's dual-revenue model [1].

CEO Dr. John T. Schiesl emphasized the company's commitment to advancing its proprietary HPP (Home Periodic Procedure) technology, aiming to leverage FDA-approved innovation for market growth despite seven consecutive quarterly losses. The stock saw 118.23% monthly gains post-earnings but remains volatile, with a 3.31% weekly decline and uncertain long-term returns [1].

Investors who purchased INVO Fertility shares and held them for 30 days saw a 25.47% gain over a three-year period, suggesting a favorable short-term market reaction. However, the annualized return of 8.16% indicates the stock's high volatility and uncertainty regarding long-term gains [1].

Looking ahead, INVO Fertility guided for continued R&D investment and cost management in 2025, with expectations of improved financial performance driven by the adoption of HPP technology and market expansion. The company did not provide specific revenue or EPS targets but remains confident in leveraging its FDA-approved innovation to capture growth opportunities in the fertility industry [1].

References:
[1] https://www.ainvest.com/news/invo-fertility-2025-q2-earnings-narrowed-loss-share-net-loss-widens-2508/